Shenyang Shengbaokang Biological Pharmaceutical

Shenyang Shengbaokang Biological Pharmaceutical is a Chinese biopharmaceutical company founded in 1999, specializing in the development and production of non-specific immunomodulators derived from bacterial extracts. The company's flagship product is Na Kejia (Lyophilized Nocardia rubra cell wall skeleton), which is approved in China for the treatment of uterine cervical erosion and has demonstrated clinical efficacy in treating HPV infections, herpes, and various skin ulcers. Shengbaokang operates manufacturing and research facilities in Shenyang and Benxi, focusing on the application of its core cell wall skeleton technology to address unmet needs in gynecology and dermatology. The company is recognized for its unique focus on bacterial-based immunotherapy and maintains a significant presence in the Chinese specialty pharmaceutical market.